Evaluated articles

A list by NCRC

Articles that have been evaluated by NCRC.

This list contains 107 articles Last updated Jan 25, 2022

This list can be subscribed to via the RSS
Find related articles using our Article recommendations
This list on Sciety

Showing page 11 of 11 pages of list content

Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection

This article's authors
1. Raymond A. Harvey
2. Jeremy A. Rassen
3. Carly A. Kabelac
4. Wendy Turenne
5. Sandy Leonard
6. Reyna Klesh
7. William A. Meyer
8. Harvey W. Kaufman
9. Steve Anderson
10. Oren Cohen
11. Valentina I. Petkov
12. Kathy A. Cronin
13. Alison L. Van Dyke
14. Douglas R. Lowy
15. Norman E. Sharpless
16. Lynne T. Penberthy
This article has 3 evaluations Latest evaluation on Mar 1, 2021 Published on Dec 20, 2020 Added on Feb 18, 2021
Multi-organ impairment in low-risk individuals with long COVID

This article's authors
1. Andrea Dennis
2. Malgorzata Wamil
3. Sandeep Kapur
4. Johann Alberts
5. Andrew D. Badley
6. Gustav Anton Decker
7. Stacey A Rizza
8. Rajarshi Banerjee
9. Amitava Banerjee
This article has 2 evaluations Latest evaluation on Mar 1, 2021 Published on Oct 16, 2020 Added on Feb 18, 2021
A Systematic Review of the Incubation Period of SARS-CoV-2: The Effects of Age, Biological Sex, and Location on Incubation Period

This article's authors
1. Caitlin Daley
2. Megan Fydenkevez
3. Shari Ackerman-Morris
This article has 2 evaluations Latest evaluation on Jan 22, 2021 Published on Dec 24, 2020 Added on Feb 18, 2021
The effect of face mask mandates during the COVID-19 pandemic on the rate of mask use in the United States

This article's authors
1. Michael J. Maloney
This article has 2 evaluations Latest evaluation on Mar 1, 2021 Published on Oct 14, 2020 Added on Feb 18, 2021
Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak

This article's authors
1. Akira Endo
2. Centre for the Mathematical Modelling of Infectious Diseases (CMMID) COVID-19 Working Group
3. Quentin J Leclerc
4. Gwenan M Knight
5. Graham F Medley
6. Katherine E Atkins
7. Sebastian Funk
8. Adam J Kucharski
This article has 4 evaluations Latest evaluation on Mar 9, 2022 Published on Aug 4, 2020 Added on Feb 18, 2021
Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

This article's authors
1. Jerald Sadoff
2. Mathieu Le Gars
3. Georgi Shukarev
4. Dirk Heerwegh
5. Carla Truyers
6. Anne Marit de Groot
7. Jeroen Stoop
8. Sarah Tete
9. Wim Van Damme
10. Isabel Leroux-Roels
11. Pieter-Jan Berghmans
12. Murray Kimmel
13. Pierre Van Damme
14. Jan de Hoon
15. Williams Smith
16. Kathryn E. Stephenson
17. Dan H. Barouch
18. Stephen C. De Rosa
19. Kristen W. Cohen
20. M. Juliana McElrath
21. Emmanuel Cormier
22. Gert Scheper
23. Jenny Hendriks
24. Frank Struyf
25. Macaya Douoguih
26. Johan Van Hoof
27. Hanneke Schuitemaker
This article has 2 evaluations Latest evaluation on Mar 1, 2021 Published on Sep 25, 2020 Added on Feb 18, 2021
Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine

This article's authors
1. Florian Krammer
2. Komal Srivastava
3. the PARIS team
4. Viviana Simon
This article has 2 evaluations Latest evaluation on Mar 1, 2021 Published on Feb 1, 2021 Added on Feb 18, 2021

Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection

Multi-organ impairment in low-risk individuals with long COVID

A Systematic Review of the Incubation Period of SARS-CoV-2: The Effects of Age, Biological Sex, and Location on Incubation Period

The effect of face mask mandates during the COVID-19 pandemic on the rate of mask use in the United States

Implication of backward contact tracing in the presence of overdispersed transmission in COVID-19 outbreak

Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial

Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine